NeoGenomics Q3 Revenue Up 11% to $209M, Raises Full-Year 2026 Guidance
NEO has more than doubled off its 52-week low of $7.065.
Summary
NeoGenomics grew Q3 revenue 11% to $209 million with adjusted EBITDA up 53% to $18.7 million, and raised full-year 2026 revenue and adjusted EBITDA guidance.
Key Events · Earnings and Guidance · NEO
-
Q3 Revenue Grows 11% to $209M
Total revenue rose 11% to $209.254 million, with clinical revenue up 13% to $195 million and NGS revenue up 29%.
-
Margins Expand, Adjusted EBITDA Up 53%
GAAP gross margin expanded 340 bps to 46.2% and adjusted EBITDA rose 53% to $18.669 million; GAAP net loss narrowed 72% to $7.546 million, or $0.06 per share.
-
Full-Year 2026 Guidance Raised
Revenue guidance lifted to $807-809 million from $802-806 million, and adjusted EBITDA to approximately $60 million from $56-58 million.
-
Balance Sheet and Cash Position
Cash and cash equivalents totaled $139.281 million at September 30, 2026, against $374.688 million of convertible senior notes, net.
Analysis · NEO · Industrial Applications And Services
Revenue of $209.3 million beat the prior full-year run-rate implied by guidance, and management lifted FY2026 revenue to $807-809 million and adjusted EBITDA to roughly $60 million. The margin story is the real change: GAAP gross margin expanded 340 bps to 46.2% and adjusted EBITDA rose 53% to $18.7 million, so the company is converting growth into profit faster than previously guided. The GAAP loss narrowed 72% to $7.5 million. Against a backdrop where the stock fell more than 12% on the October 5 CEO succession announcement, these numbers and the raised outlook are the first hard evidence that the transition is happening on a improving operating base.
How filings like this one have moved
In the 30 days to Oct 29, 2026, 31% of the 1656 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.01%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NEO was trading at $18.45 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $7.07 to $20.15. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.